ʻO ka hopena o ka Bayeta ma ka maʻi diabetes

No ka mea ua kū mai ka ʻatikala e pili ana i ka lāʻau lapaʻau ma kā mākou pūnaewele "Baeta", i hoʻohana ʻia i ka mālama ʻia ʻana o ka maʻi maʻamau ʻo 2 ʻano, ʻoi aku ka hala ma mua o hoʻokahi makahiki. I loko o kēia manawa, loaʻa ʻo "Baeta" kahi kaulana i ka wahi o nā ʻāina o ka US US mua a ua lilo i mea maʻalahi no nā maʻi maʻi maʻi.

I kēia lā e kamaʻilio hou mākou e pili ana i kēia lāʻau lapaʻau i nā kikoʻī hou aku, e noʻonoʻo i ka mōʻaukala o kāna mea inikua i maopopo ai ka hopena o ke kino o kahi maʻi maʻi, pehea e kū like ai i nā lāʻau ʻē aʻe, pehea ia e hiki ai ke kōkua a me ka mea e hoʻopilikia ai i ka mea hiki.

Ma ʻAmelika ʻAmelika, kahi ola pilikino kūikawā o nā kīola ola e hānai ana i nā manawa 3-4 wale nō i ka makahiki. I ka manawa like, hoʻopau lākou i ka nui o ka meaʻai - a i ke kolu o kā lākou kaupaona.

Ke nānā nei i kēia ʻano ʻike ʻano lua o nā holoholona hihiu, ua ʻike nā poʻe ʻepekema ʻAmelika i ka ʻaiā o ka wai puaʻa o kēia holoholona holoholona exendin. ^ E Ha yM. Ke komo ka lizards i ka digestive tract a me ka ʻōnaehana hoʻonohonoho exendin Hāʻawi i ka hāʻawi helu ʻana i nā mea kanu kino i ka wā lōʻihi. ʻO ia hoʻi, ua hoʻopuliluli ka ʻai i ka meaʻai, ʻo ia ke kumu o ka hoʻopiʻi ʻana ʻana o nā pēpē o nā holoholona.

Mahalo i nā mea hoʻololi i hoʻokō ʻia ai ka lawaiʻa o kēia holoholona, ​​ua puka mai ka lāʻau Bayeta, me ke ʻano ikaika exenatide.
ʻO ka mea kūlike o ka mālamaʻana i ka mālamaʻana i nā maʻi diabetes type 2 he mea ia e kōkua ai i ka hōʻemi i ke kaumaha o ke kino o ka mea maʻi. ʻOiai ʻo ka hapa nui o nā lāʻau lapaʻau i hoʻohana ʻia no ke kumu like ua alakaʻi i ka hopena kū'ē.

Inā ʻoe e noʻonoʻo e ʻoi kekahi o nā kumu o kēia maʻi ma luna o ka momona a me ka momona, a laila ke hoʻohana ʻia diabetes type 2 hiki ke manaʻo ʻia e like me ka hopena i nā pilikia ʻelua i ka manawa like.

Wahi a nā loiloi a me nā ʻano waihona like ʻole, hoʻohana ʻia ka nui i ʻelua i kēlā me kēia lā. I kēia hihia, ʻaʻole i hoʻohana ʻia ka insulin. Akā ke ʻano lapaʻau type 2 pili i ka hoʻohana ʻia ʻana o kekahi mau lāʻauʻokoʻa.
ʻO ka hoʻokomo ʻana o ka lāʻau byte e lawe ʻia ana i loko o ka ʻāhā, forearm a ʻōpū paha, i ka momona subcutaneous. Hoʻohana ʻia kahi penikala syringe maʻamau no kēia.

Hiki ke hoʻohana wale ʻia ʻo Byte e mālama i ka maʻi maʻi type 2. ʻAʻole ia e hoʻohana i ka lāʻau lapaʻau i mua o nā maʻi e like me ka ketocidosis maʻi maʻi, i ʻole ke kūleʻa ʻana, nā maʻi gastrointestinal maʻi, a me ka hoʻonui hou ʻana i nā mea like ʻole o ka lāʻau.

ʻAʻole hiki ke kuhikuhi ʻia ʻo Bayeta i nā keiki ma lalo o ka 18 mau makahiki o ka makahiki, e hoʻohana ana i ka wā o ka wā hāpai a i ka wā hānai.

Aia ke aʻo.

Hoʻohana ʻia ka lāʻau lapaʻau i 1 hola ma mua o ka papaʻaina, ʻelua manawa i ka lā. Kakau ʻia ka dosage, kona hōʻemi a hoʻonui ʻana paha i ke kūkākūkā ʻana me ke kauka e komo ana.

ʻAʻole hiki iā ʻoe ke hoʻohana i ka lumi kaukau inā nānā mai ke anuanu o ka hopena, ua ʻike ʻia nā ʻāpana like ʻole i loko a i ʻole ke kala ʻaihue. ʻAʻole hōʻike ʻia e hoʻohana koke ma hope o ka ʻai ʻana. ʻAʻole noʻonoʻo ʻia ka hoʻokele Intramuscular a intravenous i kahi hoʻonā.

Ke hoʻohana ʻia i nā antibiotika like ʻole, pono lākou e lawe i hoʻokahi hola ma mua o ka hoʻokō ʻana o nā lāʻau lapaʻau.

Ma mua o ka hoʻohana ʻana i ka lāʻau Baeta no ka mālama ʻana i ka maʻi maʻi type 2, pono pono e nīnau i ke kauka!

Inoa Kūʻai ʻole honua

INN Bayeta - Exenatide.

ʻO Baeta kahi lawehala hypoglycemic i hoʻolālāʻia e mālama i ka maʻi II ʻano II, kahi huahana lapaʻau maikaʻi loa.

No ka lāʻau lapaʻau i ka hui o ka pharmacological o nā māmene hypoglycemic synthetic i manaʻoʻia no ka mālamaʻana i ka mellitus diabetes-hilinaʻi, a loaʻa kahi code ATX o A10X.

E hoʻokuʻu i nā palapala a me ka ʻano

Loaʻa ka lāʻau lapaʻau i ke ʻano o kahi hoʻonā inikua i hoʻohana ʻia no ka hoʻokele subcutaneous. He maemae hoomaemae, he aniani a me ka aila ala. ʻO kāna mea kūlohelohe exenatide he lō ʻo 250 μg no 1 ml o ka hoʻonā. Hoʻāla ʻia ka hana o ka hāmeʻala e ka wai wana, a ʻo ka hoʻopiha hoʻopili pili i hōʻike ʻia e ka metacresol, sodium acetate trihydrate, acetic acid, a me ka mannitol (hoʻohui ʻia E421).

Kūkulu ʻia kahi hopena o 1,2 ai ʻole 2.4 ml i loko o nā pahu pahu aniani, ʻo kēlā me kēia mea i kau ʻia ma kahi penikala syringe peni - kahi hoʻohui o ka injector insulin. ʻŌwili pahu kūmole. Aia wale nō kahi 1 syringe me ka lāʻau lapaʻau i ka pahu.

Loaʻa kahi hoʻomākaukau hoʻihoʻi e loaʻa nei i ka pauka hoʻopukapuka no ka hoʻomākaukau ʻana o ke ʻano hoʻopiʻi. Hoʻohana ʻia ka ʻano hopena no ka hoʻonā subcutaneous. ʻO ka waiwai momona (2 mg) e ninini ʻia i loko o kahi pahu i kau ʻia ma kahi peni syringe. Aia ka pahu i kahi hāmeʻa injectable a me nā ʻōlelo aʻoaʻo.

ʻO Bayeta kahi pahu kī aniani me kahi hopena injectable no ka hoʻokele subutaneus, hoʻokomo ʻia i nā syringes disable.

Ka hana lāʻau lapaʻau

Hāʻawi ka hopena o ka lāʻau i ka hana a exenatide (exendin-4).

ʻO kēia hoʻohui synthetic he amino peptide chain e kū ana i nā 39 o nā mea waikawa amino.

ʻO kēia ʻano he mea hoʻohālikelike o ka enteroglucagon - ka peptide hormone a me ka hua pume i hoʻokumu ʻia i loko o ke kino o ke kanaka, ka mea i kapa ʻia ʻo kaagonona-like peptide-1, a i ʻole GLP-1.

Hoʻohui ʻia ka nui o nā huaʻai i nā huaʻai o ka pancreas a me nā ʻōpū ma hope o kahi pāʻina. ʻO kā lākou hana, ʻo ka hoʻomaka ʻana i ka huna ʻana i ka insulin. Ma muli o kona like me kēia mau mea hormonal, he like ka hopena o exenatide ma ke kino. Hana ʻia e like me ka mimula a GLP-1, hōʻike ʻia i kēia mau kūlana therapeutic:

• hoʻonui i ka hoʻokuʻu ʻana o ka insulin e ka pancreatic β-cells me ka hoʻonui ʻana i ka hoʻoliʻi glucose glucose,
• hōʻemi i ka huna nui o ka glucagon, me ka hoʻoluhi ʻole ʻana i ka pane mai ka hypoglycemia,
• pale i ka ʻeke a ka ʻōpū, e hoʻolohi ana i kona nehe ʻana,
• e hoʻoponopono i ka momona
• hoʻemi i ka nui o nā meaʻai i ʻai ʻia,
• paipai i ka pohō kaumaha.

Nā ʻōlelo kuhikuhi Byetta - Applace He aha ke ʻano maʻi diabetes 2 ma nā huaʻōlelo maʻalahi

Ma ka maʻi diabetes type 2, paʻa ka hana o ka pancreatic β-cell, ka hopena o ka komo ʻana o ka huna ʻana o ka insulin. Hoʻopilikia ka Exenatide i nā lua ʻelua o ka ʻenekina insulin. Akā i ka manawa like, ʻo ka nui o ka hana o nā β-cell i hoʻomaka ʻia e ia e hoʻemi me ka hoʻohaʻahaʻa o ka neʻe o ka glucose. Ke kū nei ka manaʻo o ka insulin i ka manawa ke hoʻi hou nei ka loulou glycemic i ke ʻano maʻamau. No laila, ʻo ka hoʻomakaʻana o ka lāʻau i ka nīnau e hōʻemi i ka hiki ke hoʻoulu i ka hypoglycemia.

Ua hōʻike ʻia nā haʻawina haukapila e hiki ai i kēlā mau maʻi ke ana i ka mālama pono o ke kō koko koko i nā mea maʻi me ka maʻi diabetes type 2.

Lapaʻau lāʻau

Ma hope o ka hoʻokele ʻana o Baeta ma ke ʻano o kahi maʻi subcutaneous, hoʻomaka ke lāʻau lapaʻau e hoʻokomo i ka koko, a hiki i ka pae nui loa o ka saturation i loko o kahi mau hola 2.

ʻO ka nui o ke kaila o ka exenatide hoʻonui i ke kūlike i ka nui i loaʻa i ka wa i 5-10 μg.

Loaʻa ka lāʻau lapaʻau ʻo Baeta i ka nui o ka saturation i loko o ke koko 2 mau hola ma hope o ka hoʻokele subcutaneous a hoʻopau loa mai ke kino i loko o 10 mau hola.

Lawe ʻia ka kānana ʻana i ka lāʻau lapaʻau e nā kumu ʻai moku, hoʻopili ʻia nā enzyme proteolytic i kāna metabolization. 5 mau hola he 5 e wehe i ka nui o ka lāʻau lapaʻau mai ke kino, me ke ʻano o ka dosis i hoʻohana ʻia. ʻO ka hoʻomaʻemaʻe holoʻokoʻa o ke kino e lawe i nā hola 10.

Nā hōʻailona no ka hoʻohana ʻana

Hōʻike ʻia ka lāʻau lapaʻau no ka hoʻoponopono ʻana i ka maʻi glycemic kūpono ma ke ʻano o ka maʻi diabetes. Hiki ke hoʻohanaʻia e Byetu ma ke ʻano he lāʻau hypoglycemic no ka monotherapy. Kahi ʻia kahi ʻoiʻi maikaʻi ʻia e hoʻolako ʻia kahi mea kūpono kūpono e hoʻomaʻamaʻa ʻia a hoʻomaʻamaʻa ʻia nā ʻano therapeutic maʻamau.

Hiki ke hoʻohui ʻia kēia lāʻau lapaʻau i loko o kahi papa i hoʻohui pū ʻia me ka lawa ʻole o ka mālama ʻana me nā lawena antiglycemic ʻē aʻe. Hoʻohui ʻia kekahi mau lāʻau lapaʻau me Bayeta:

1. ʻO Sulfonylurea derivative (PSM) a me Metformin.
2. Metformin a me Thiazolidinedione.
3. PSM me Thiazolidinedione a me Metformin.

Kēia mau ʻano hana e alakaʻi i ka emi ʻana o ke kō koko wikiwiki a ma hope o ka ʻai ʻana, a me ka hemoglobin glycemic hoʻi, e hoʻomaikaʻi ana i ka mana glycemic ma o nā mea maʻi.

Ua kuhikuhi ʻia ʻo Bayeta no ka hoʻoponopono ʻana o ka glycemic kūpono, a hiki ke hoʻohana ʻia no ka monotherapy.

Nā Hoʻohui

ʻAʻole hiki ke hoʻohana ʻia ka lāʻau lapaʻau no ka maʻi diabetes type 1. Nā maʻi ʻē aʻe:

• hoonui o ka lae ai exenatide,
• lololo iā nā hoʻohui hoʻohui,
• ketoacidosis
• hōʻino i ka hana o ka digestive tract, piha pū me ka hoʻoneʻe ʻana i ka hana kontrakile o nā ʻeha o ka ʻōpū
• ka ipo a me ka hāpai ʻana,
• pilikia kaumaha ʻole
• makahiki i 18 makahiki.

ʻO ka maleʻe kekahi o nā contraindications no ka hoʻohana ʻana i ka lāʻau lapaʻau Bayet.

Pehea e lawe ai i ka bayetu?

Na ke kauka ke kuleana no ke kuhikuhi ʻana i ka lāʻau lapaʻau, e hoʻoholo ana i nā palena kūpono loa a nānā i ke ʻano o ka mea maʻi me ka maʻi maʻi. Ua koi ikaika ʻia ʻoe e hōʻole i ka lapaʻau ponoʻī iho iā ʻoe iho.

Hoʻopuka ʻia nā ʻōkuhi ma lalo o ka ʻili i ka wahi brachial, femoral a i ʻole nā ​​ʻōpū. ʻAʻole pili ka pūnaewele injection o ka lāʻau i kona kū pono.

I ka wā mua, ʻo kahi waihona hoʻokahi he 0.005 mg (5 μg). Hāʻawi ʻia kahi palapala ma mua o ka ʻaina kakahiaka a me ka ʻaina awakea. ʻO ka pale kuʻuna ma waena o ka hoʻolauna ʻana i ka lāʻau a me ka hoʻomaka ʻana o ka ʻai ʻana ʻaʻole e hala i kahi hola 1.

Ma waena o nā papaʻai nui, ka mea i pili me ka hoʻohana ʻana i ka lāʻau lapaʻau, ma ka liʻiliʻi he 6 mau hola e hala.

Ma hope o hoʻokahi mahina o ka mālama ʻana, hiki i ka pālua hoʻokahi ke pālua. ʻAʻole i loaʻa ka maʻi i hala ka piʻi ʻana me ka hoʻonui ʻana i nā kao me ka hoʻokele hou ʻana o ka lāʻau. Ma hope o ka ʻai ʻana iā Bayetu ʻaʻole pono ia e paʻi.

Me ka hoʻohana 'ana i ka lāʻau lapaʻau i nīnau ʻia me kahi mākaukau o ka sulfonylurea, hiki i ke kauka ke hōʻemi i ka nui o ka hopena ma muli o ka hiki i ka hoʻomohala ʻana o ka hopena hypoglycemic. Hoʻohui ʻole kahi hui me Thiazolidinedione a me / a i ʻole Metformin i kahi loli i nā pulu mua o kēia mau lāʻau.

Nā hopena hopena

ʻO nā hopena ʻino e hoʻoili ai e ka exenatide he ʻeha ʻeha a ʻaʻole pono i ka hoʻokuʻu ʻana o ka lāʻau (me nā mea ʻokoʻa ʻole). ʻO ka pinepine, ma ka hoʻomaka mua o ka mālama ʻana me Bayeta me ka nui o ka nui o 5 mg a i ʻole ka mg 10 mg, puka mai ka nausea, e nalo ana iā ia iho ma hope o ka hoʻoponopono ʻana o ka hoʻoulu.

ʻO ka loiloi he hana ʻino e pili ana i ka hana a ka lāʻau lapaʻau Bayet, hōʻike pinepine ʻia i ka laʻi mua o ka mālama ʻana.

ʻŌpala Gastrointestinal

I ka manawa pinepine, ua loaʻa ka maʻi maʻi i kahi hāpana. Hoʻopiʻi ka poʻe maʻi i ka nausea, ka nalowale o ka makemake, ka luaʻi, ka dyspepsia, ʻeha i loko o ka ʻōpū. Hiki paha ke ʻoli, ke ʻano o ke belching, ʻiliʻu, constipation, ʻae ʻole i ka ʻike ʻono. Ua hōʻike ʻia he mau hihia o ka pancreatitis maʻa.

Pūnaehana pīhoihoi waena

Loaʻa i nā maʻi maʻi he migraines. Pane paha lākou i ka pīhoihoi a i ʻole ka ʻike ʻana i ka hiamoe o ka lā.

ʻO ka migraines he hopena maʻamau e pili ana i ka hoʻohana ʻana o ka lāʻau Bayet mai ka pūnaehana pīhoihoi waena.
I ka hopena o ka hoʻohana ʻana i ka lāʻau Bayeta, hiki i ka mea maʻi ke hōʻeha i nā maʻi.
ʻO ka hopena o ka hiamoe hiamoe i ke ala kūpono paha ke hoʻohana ʻia ma ka Byeta.

Ma ka ʻāpana o ka ʻili

Ma ka wahi i ʻōlelo ʻia, ʻike ʻia nā hōʻailona pili pono.

Hiki ke kūlou i nā ʻōmaʻomaʻo i ke ʻano o ka palahalaha i ka ʻili, hōʻeha, ʻulaʻula, ke kuehue. Loaʻa nā hōʻike anaphylactic i ʻike pinepine ʻia.

ʻO ka hōʻeha ʻeha ka hōʻeha kūloko me ka hoʻohana ʻana i ka lāʻau o Bayet.

Nā ʻōlelo kikoʻī

Inā hoʻololi ʻia ke kala, pololi a ʻiliʻili ʻana o ka wai ʻauʻau, ʻaʻole hiki ke hoʻohana ʻia. Pono ʻoe e pili i ke ʻano i hāʻawi ʻia i ka hana o ka lāʻau lapaʻau. ʻAʻole i kuhikuhi ʻia nā ʻōkuhi intramuscularly a i ʻole intravenously.

ʻO ka hakina o ka makemake a i ka loaʻa ʻana o ka momona kaumaha o ka mea maʻi ʻaʻole kahi hōʻailona no ka hoʻokuʻu ʻana i nā lāʻau lapaʻau, he hoʻololi ma kona ʻano nui a me ka loaʻa ʻana o ka hoʻohana ʻana.

I ka paneʻana i ka hoʻokomoʻana i ka exenatide, hiki ke hoʻoulu ʻia nā antibodies i loko o ke kino. ʻAʻole pili kēia i ka hōʻike ʻana o nā hōʻailona pili.

Hoʻohana i ka wā kahiko

ʻAʻole hilinaʻi ka pharmacokinetics o ka lāʻau lapaʻau i ka makahiki o nā mea maʻi. No laila, ʻaʻohe mea e pono ai ke hoʻoponopono ʻia no ka ʻelemakule.

ʻAʻole kahiko ke ʻano o ka wā kahiko no ka hoʻohana ʻana i ka lāʻau lapaʻau Bayet, a ʻaʻohe no hoʻi e koi i ka hoʻoponopono ʻana i ka nui o ka lāʻau.

Ke noi no ka hana lawelawe lēʻaleʻa

Ma muli o ka hana nui o ka lawe ʻana i ka exenatide hāʻule ma luna o ka pūpū, nā kuhi hewa o ka ʻūpoki a i ʻole ʻoloka paha he contraindication no ka hoʻohana ʻana i ka lāʻau lapaʻau a mai hoʻopiʻi i nā mea keʻake.

ʻO ka hana ʻole i ka puhaka a i ʻole ʻohi ai ʻaʻole ia he contraindication no ka hoʻohana ʻana i ka lāʻau.

Ke kumuwai o Byeta

ʻO ka ikaika nui o nā dosis i hōʻike ʻia e exenatide e alakaʻi i ka hypoglycemia. I kēia hihia, pono ke koi a ʻokiʻoki paha i ka maʻi glucose. Nā hōʻailona o kahi overdose:

• pīhoihoi o ka ʻōpū
• utuka
• haʻahaʻa glucose glucose
• pallor of integument,
• mea ʻalaʻawa
• lie kanikela
• kaohuu
• ireliaia,
• piʻohū
• hoʻonui i ke koko:
• hāpau.

ʻO Arrhythmia kekahi o nā hōʻailona o kahi overdose o Bayet.

Hoʻopili pū me nā lāʻau ʻē aʻe

Ke kāwili ʻia ʻana o ka hoʻonā ʻia me nā lāʻau injectable'ē aʻe i 1 syringe ua pāpā ʻia.

Pono ʻoe e noʻonoʻo i ka hoʻolimalima o ka ʻōpū ma lalo o ka hana a exenatide i ka wā e lawe ai i nā lāʻau lapaʻau i loko, no ka mea, hiki ke hōʻemi nui ʻia ka pae ʻana o ka ʻōpū. Pono ka lōʻihi o kēia mau kālā ma mua o ka hoʻokomo ʻana o Byeta, ʻo ka palena manawa he 1 hola. Inā makemake ʻia ka lāʻau lapaʻau me ka meaʻai, a laila ʻaʻole ia he pāʻina ʻaʻole i hui pū ʻia me ka ʻaina a kēia puʻuwai hypoglycemic.

Pono e hoʻopaʻa ʻia nā mea pale aku proton 4 mau hola ma hope o ka ʻōlelo ʻana a i ʻole 1 hola ma mua.

Me ka hoʻohana pono ʻana o ka warfarin a i ʻole ka hoʻomākaukau ʻana o nā coumarin, hiki i ka hoʻonui ʻana o ka manawa prothrombin. No laila e hoʻomoka pono i ka coagulation koko.

ʻOiai ka hoʻohana pū ʻana o Bajeta me nā lāʻau lapaʻau e pale ana i ka HMG-CoA reductase, ʻaʻole ia i nā loli nui i ka lipid komposisyon o ke koko, ua manaʻo ʻia e nānā pono i ka ʻōkuhi kolala.

ʻO ka hui pū ʻana o ka lāʻau i nīnau ʻia me Lisinopril, ʻaʻole ia e loli i ka loli iki o ke koko o ka mea maʻi.

ʻO ka hoʻohui ʻana i nā kaha o Bajeta me nā mea kūlohelohe wahaʻa, ʻaʻole pono e loli i ka dosage.

ʻAʻole pono ke nānā i kekahi mau pilina kūikawā ma waena o nā inikini a me ka hoʻouka ʻana i nā lāʻau lapaʻau - derivatives o ka sulfanylurea.

Me ka hui pū ʻana / me ka hoʻokau ʻana o Bayeta me Warfarin, pono ia i ke kāohi ʻana i ka ʻaila koko.

Hoʻolaha ka waipuna

ʻAʻole kūpono loa e hoʻopau i ka waiʻona a i ʻole nā ​​lāʻau lapaʻau no ka waiʻona i ka wā e mālama ai.

Aia wale kahi 2 mau mea kikoʻī āpau o ka lāʻau - Exenatide a me Baeta Long. ʻO nā huaʻōlelo hypoglycemic penei:

Kaʻina Baeta - Bydureon (Bydureon).

ʻO Victoza kahi kikowaena hypoglycemic like me ka like me Bayeta.

ʻO ka lā kau

I kāna hana kumu, mālama ʻia ka lāʻau lapaʻau no 2 mau makahiki. Ma hope o ka wehe ʻana i ka pākau, pono e hoʻohana ʻia i loko o 30 mau lā.

ʻO 2 mau makahiki i kona kūlana kumu a me 30 mau lā ma hope o ka wehe ʻana i ka paena.

Mea hana

ʻO ka'āina i ʻōlelo ʻia ʻo Pelekānia Nui. Eia naʻe, ʻo ka hana o ka lāʻau i mālama ʻia e ka ʻenehana lāʻau lapaʻau ʻĀina e Macleods Pharmaceuticals Ltd.

Alla, 29 makahiki, Stavropol.

A kūʻai aku au i ka makuahine o Baitu. Mākaukau, akā maʻalahi ia e hoʻohana. I ka wā mua, ua ohumu ʻo mama ua kuʻakeʻa ia, akā, i ka manawa koke.Kūpaʻa ka Sugar, no laila e hoʻomau mākou i ka hoʻohana ʻana i ka lāʻau lapaʻau.

Veronika, 34 makahiki, Danilov.

Ke heluhelu hou nei wau i nā ʻōlelo kuhikuhi, ʻaʻole wau mai i ka papa inoa o nā hopena hopena. Ma hope o ka ʻōlelo hahau ua maʻi au. Ua makaʻu wau i ka hoʻokele e pili ana i ka hopena hou. Akā ua ʻōlelo kaʻu kāne ua hoʻopunipuni wau iaʻu iho. Ua pono. ʻAʻoheʻoi loa ka hōʻeha ʻana. ʻ saidlelo ke kauka ʻaʻole pono ka mokuahi, a ʻoi aʻe ka hoʻonui. I kēia manawa ʻaʻole ona hopohopo hou ʻana i ka maʻi, aia i kekahi manawa aia kahi pōʻino i loko o ka ʻōpū.

Olga, he 51 makahiki, ke kūlanakauhale o Azov.

Hoʻomaka wau e hoʻohana i ka lāʻau lapaʻau e kōkua i ka Metformin. ʻAi ʻo ia i nā lā mua ma o ka ikaika - ua pau loa kāna makemake. A laila paʻa ka kino. Ua liʻiliʻi nā wahi, akā ua hoʻihoʻi ka makemake. ʻĀnō maopopo ke kumu no ka makemake ʻana o ʻAmelika Hui Pū ʻIa no nā poʻe makemake e nalowale kaupaona.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

i nā peni syringe me nā pahu pahu o 1,2 a 2.4 ml paha, i loko o kahi pā kāleka 1 peni syringe peni.

Lapaʻau lāʻau

ʻO Exenatide (Exendin-4) kahi mimetin mimetic a he 39-amino acid amidopeptide. ʻO ka mea nui, e like me ka peptide-like glucagon-1 (GLP-1), e hoʻonui i ka huna ʻana i ka glucose o ka glucose, e hoʻomaikaʻi i ka hana cell cell, e hōʻoki i ka hoʻonui ʻia ʻana o ka pale me ka hoʻokaʻawale i ka ʻōpū ma hope o kā lākou komo ʻana i ke kaila maʻamau mai nā ʻōpū. He exenatide kahi mimetic mimetin ikaika e hoʻonui ai i ka huna ʻana i ka glucose o ka glucose a loaʻa nā hopena hypoglycemic i loaʻa i ka incretins, e hoʻomaikaʻi ana i ka mana glycemic i loko o nā mea maʻi me ka maʻi diabetes type 2.

ʻO ka papa waikawa amino o ka exenatide mahele like me ka pakanui o ke kanaka GLP-1, ma muli o ia mea e nakinaki ai a hoʻonā i nā mea hoʻonaninani GLP-1 i loko o nā kānaka, e alakaʻi ana i ka synthesis-hilinaʻi nui o ka glucose a me ka huna ʻana o ka insulin mai ka pancreatic beta cells me ka komo ʻana o ka cyclic adenosine monophosphate (AMP) a me / a i ʻole mau alanui e hōʻailona holomua. Hoʻokomo ʻo Exenatide i ka hoʻokuʻu ʻana o ka insulin mai nā beta beta i mua o ka piʻi ʻana o ka glucose kiʻekiʻe.

Hoʻolaha ka Exenatide i ka hana kemika a me nā hana farmacological mai ka insulin, derivatives sulfonylurea, D-phenylalanine derivatives a me meglitinides, biguanides, thiazolidinediones a me nā alpha-glucosidase inhibitors.

Hoʻonui ka Exenatide i ka mālama glycemic i nā maʻi me nā maʻi type 2 no ka mea hana i hōʻike ʻia ma lalo nei.

I nā kūlana hyperglycemic, hoʻonui ka exenatide i ka huna ʻana i ka glucose i ka huna ʻana i ka insulin mai nā cell beta pancreatic. Ua kāpae kēia mea huna huna i ka hoʻōla ʻana o ka glucose i ke koko a ke hoʻokokoke nei ia i ka maʻamau, a laila e hōʻemi ʻia ka hopena o ka hypoglycemia.

ʻO ka huni ʻana o ka insulin i nā minuke 10 mua, i kapa ʻia ʻo ka "mana mua o ka pane ʻana i ka insulin", ʻaʻole ia i loko o nā mea maʻi me ka diabetes type 2. Eia nō kekahi, ʻo ka lilo ʻana o ka hana mua o ka pane ʻana i ka insulin he hana pōkole o ka hana o ke cell beta i ka maʻi type 2. hoʻihoʻi a hoʻonui koʻikoʻi paha i ka hoʻomaka mua a me ka lua o ka pane ʻana i ka insulin i nā mea maʻi me ka maʻi maʻamau 2.

I ka maʻi me ka diabetes type mellitus kū'ē i ke kua o ka hyperglycemia, ke hoʻomalu nei ka hana o ka exenatide i ka nui o ka huna ʻana o ka glucagon. Eia nō naʻe, ʻaʻole e hoʻopili ʻo exenatide i ka pane o ka glucagon maʻamau i ka hypoglycemia.

Hōʻike ʻia ka alakaʻi ʻana o ka exenatide i kahi hoʻohaʻahaʻa i ka momona a me ka hoʻohaʻahaʻa ʻana i ka ʻai o ka meaʻai, ke kāohi i ka kaomi o ka ʻōpū, kahi e alakaʻi ai i ka lohi i kona hoʻokaʻina ʻana.

I nā mea maʻi me ka diabetes mellitus type 2, ʻo ka exenatide therapy i hui pū me ka metformin a me / a i ʻole ka hoʻomākaukau ʻana i ka haʻalulu sulfonylurea e hōʻemi i ka wikiwiki o ka hoʻokaʻa ʻana o ke koko glucose, glucose glucose postprandial, a me ka glycosylated hemoglobin index (HbA1c), ma laila e hoʻomaikaʻi ai i ka mālama glycemic i kēia mau maʻi.

ʻLoe a me ke kākele

S / c i ka ʻūhā, ka ʻōpū, a me ka manamana lima.

ʻO ka dosis mua ka 5 mcg, ka mea i mālama ʻia i nā manawa 2 / lā i kēlā me kēia manawa i ka manawa o 60-minuke ma mua o ke kakahiaka a me ke ahiahi ʻaina. Mai alakaʻi i ka lāʻau lapaʻau ma hope o ka ʻaʻa ʻana. Inā pau ka loaʻa ʻana o ka lāʻau lapaʻau, hoʻomau ka mālama ʻana me ke hoʻololi ʻana i ka nui.

1 mahina ma hope o ka hoʻomaka ʻana o ka mālama ʻana, hiki ke hoʻonui ʻia ka nui o ka lāʻau i ka 10 mcg i nā manawa 2 / lā.

Ke hui pū nei me ka metformin, thiazolidinedione, a i ʻole me ka hoʻohui ʻana i kēia mau lāʻau, ʻaʻole hiki ke loli i ka hopena mua o ka metformin a me / a thiazolidinedione wale nō. I ka hihia o ka hui pū ʻana o Bayeta ® me ka derivatives sulfonylurea, pono e hoʻemi ʻia ka nui o ka derivative sulfonylurea e hōʻemi i ka hopena o ka hypoglycemia.

ʻO ka hapa a me ke ala o ka hoʻokele ʻana o ka lāʻau BAETA

Hana ʻia nā lāʻau i nā s / c i loko o ka ʻōpū, ka ʻōpū, ke poʻohiwi.

ʻO ka dosis mua he 5 mcg, mālama ʻia ʻelua mau manawa i ka lā, no 60 mau minuke ma mua o ka ʻaina kakahiaka a me ka ʻaina. Ma hope o ka ʻai ʻana, ʻaʻole i ʻōlelo ʻia ka lāʻau lapaʻau. Inā pau ka loaʻa ʻana, ʻaʻole e hoʻokaʻawale i ka nui ma ka wā o ka hoʻokō ʻana.

Hoʻonui ʻia ka dosage i loko o hoʻokahi mahina ma ka 10 mcg ʻelua i kēlā me kēia lā.

ʻO ka maʻi diabetes type 2: monotherapy a i ʻole he hoʻohui i ka mālama ʻana me ka metformin, sulfonylurea a me nā lāʻau ʻoiia thiazolidinedione me ka make ole o ka maʻi glycemic.